ArticleDiscover oncology2025
Identification of prognostic genes associated with mitochondria and macrophage polarization in prostate adenocarcinoma based on transcriptome and Mendelian randomization analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nucleotide metabolic reprogramming: a "double-edged sword" in obesity-related inflammation-from metabolic adaptation to pathological imbalance.Journal of physiology and biochemistry · 2026Review
- Single-cell and bulk transcriptomic analyses identify B-cell senescence-associated biomarkers in papillary thyroid carcinoma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate adenocarcinoma (PRAD) is a common malignancy in the male genitourinary system, with growing evidence linking its progression to mitochondrial function and macrophage polarization. This study identifies prognostic genes associated with these factors in PRAD through integrated transcriptomic data analysis and Mendelian randomization (MR).
methodsThis study utilized transcriptome datasets from The Cancer Genome Atlas prostate adenocarcinoma (TCGA-PRAD). Candidate genes were selected by integrating mitochondrial-related genes (MRGs), macrophage polarization-related genes (MPRGs), and differentially expressed genes (DEGs). Prognostic genes were subsequently identified through MR and regression analyses, enabling the construction and validation of a risk prediction model. The model underwent independent prognostic assessment and nomogram validation, followed by comprehensive analyses including functional enrichment, immune profiling, and drug sensitivity evaluation comparing high- and low-risk cohorts.
resultsFrom the overlap of 6,734 DEGs, 5,940 key module genes, and 1,136 MRGs, 103 CGs were identified. MR and regression analyses revealed seven prognostic genes (ABHD11, PTRH2, CAT, NTHL1, SLC25A39, OXR1, GSTZ1), which formed a robust risk prediction model. The model confirmed risk score, prostate-specific antigen, and Gleason score as independent prognostic factors for PRAD. A validated nomogram demonstrated high accuracy in outcome prediction. Functional enrichment analysis highlighted differential E2F target activity between risk groups, while immune profiling identified nine distinct cell populations, including immature dendritic cells. Finally, drug sensitivity analysis showed elevated IC50 values for bexarotene and CCT018159 in high-risk patients.
conclusionThis study identified seven prognostic genes and provided a new theoretical basis for exploring immune defense mechanisms and targeted therapeutic drugs in PRAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.